Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - indacaterolum, glycopyrronium - poudre pour inhalation en gélule - indacaterolum 110 µg ut indacateroli maleas, glycopyrronium 50 µg ut glycopyrronii bromidum, lactosum monohydricum, magnesii stearas, pro capsula. - maladie pulmonaire obstructive chronique (mpoc) - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - indacaterolum, glycopyrronium, mometasoni-17 furoas - hartkapsel mit pulver zur inhalation - indacaterolum 150 µg ut indacateroli acetas, glycopyrronium 50 µg ut glycopyrronii bromidum, mometasoni-17 furoas 160 µg, lactosum monohydricum 24..567 mg, magnesii stearas, kapselhülle: hypromellosum, carrageenanum, kalii chloridum, e 172 (flavum), e 132, aqua purificata, cera carnauba, drucktinte: aqua purificata, e 172 (nigrum), alcohol isopropylicus, propylenglycolum, hypromellosum pro capsula. - asthma - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - indacaterolum, mometasoni-17 furoas - poudre pour inhalation en gélule - indacaterolum 0.150 mg ut indacateroli acetas, mometasoni-17 furoas 0.080 mg, lactosum monohydricum, kapselhülle: gelatina, pro capsula. - asthma - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - indacaterolum, mometasoni-17 furoas - poudre pour inhalation en gélule - indacaterolum 0.150 mg ut indacateroli acetas, mometasoni-17 furoas 0.160 mg, lactosum monohydricum, kapselhülle: gelatina, pro capsula. - asthma - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - indacaterolum, mometasoni-17 furoas - poudre pour inhalation en gélule - indacaterolum 0.150 mg ut indacateroli acetas, mometasoni-17 furoas 0.320 mg, lactosum monohydricum, kapselhülle: gelatina, pro capsula. - asthma - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - indacaterolum - poudre pour inhalation en gélules (avec l'inhalateur) - indacaterolum 150 µg ut indacateroli maleas, lactosum monohydricum, kapselhülle: gelatina, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, pro capsula, corresp. indacaterolum 120 µg pro dosi. - la mpoc - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - indacaterolum - poudre pour inhalation en gélules (avec l'inhalateur) - indacaterolum 300 µg ut indacateroli maleas, lactosum monohydricum, kapselhülle: gelatina, drucktinte: lacca, e 133, propylenglycolum, e 171, e 172 (nigrum), pro capsula, corresp. indacaterolum 240 µg pro dosi. - la mpoc - synthetika

Union européenne - français - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - asthme - les médicaments pour les maladies respiratoires obstructives, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Union européenne - français - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - asthme - les médicaments pour les maladies respiratoires obstructives, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Union européenne - français - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - asthme - les médicaments pour les maladies respiratoires obstructives, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.